BALTIMORE, June 11, 2020 (GLOBE NEWSWIRE) — Glyscend Therapeutics, a privately held biopharmaceutical company developing novel treatments for type 2 diabetes (T2D) and related metabolic conditions, today announced the closing of a $20.5 million Series A financing round. Healthcare investors Brandon Capital Partners, through its Medical Research Commercialisation Fund (MRCF), and Santé Ventures led the round of funding, which will be used to support the development of the company’s novel oral polymer therapy for patients with T2D and other metabolic diseases. Breakout Labs (a fund in the Thiel Foundation) provided seed funding in 2019.
{iframe}https://www.globenewswire.com/news-release/2020/06/11/2047000/0/en/Glyscend-Therapeutics-Completes-20-5M-Financing-Round-to-Advance-Novel-Oral-Polymer-Therapy-for-Type-2-Diabetes.html{/iframe}